Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating.
On the company’s first-quarter 2026 earnings call, CEO Mark L. Baum said the quarter’s headline revenue figure reflected “a specific isolated dynamic” rather than a deterioration in demand. Harrow reported consolidated revenue of $44.2 million and adjusted EBITDA of negative $12.7 million for the quarter, according to President and Chief Financial Officer Andrew Boll.
